Noxopharm Half-Year Loss Widens as Net Tangible Assets Turn Negative

The latest update is out from Noxopharm Ltd. ( (AU:NOX) ).

Noxopharm Limited reported a sharp widening of its half-year loss to $1.84 million for the period ended 31 December 2025, a 49% increase from the prior corresponding period’s $1.24 million loss. The company’s net tangible assets per share fell into negative territory at minus 0.39 cents from 0.24 cents, and no dividends were paid or declared, underscoring ongoing funding needs and the capital-intensive nature of its development-stage operations.

The absence of dividends for both the current and previous half-year periods highlights Noxopharm’s continued focus on reinvesting resources into its pipeline rather than returning capital to shareholders. With no changes in control, associates or joint ventures reported, the results primarily reflect internal cost structures and investment in R&D, leaving investors focused on the company’s ability to translate its spending into future clinical and commercial milestones.

The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.

More about Noxopharm Ltd.

Noxopharm Limited is an Australian biopharmaceutical company focused on developing oncology and related therapies. The company operates in the life sciences sector, targeting unmet medical needs through research-driven drug development aimed at improving treatment outcomes for patients.

Average Trading Volume: 172,577

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$20.46M

For an in-depth examination of NOX stock, go to TipRanks’ Overview page.